WO2008045419A1 - Preparation of nucleosides ribofuranosyl pyrimidines - Google Patents

Preparation of nucleosides ribofuranosyl pyrimidines Download PDF

Info

Publication number
WO2008045419A1
WO2008045419A1 PCT/US2007/021548 US2007021548W WO2008045419A1 WO 2008045419 A1 WO2008045419 A1 WO 2008045419A1 US 2007021548 W US2007021548 W US 2007021548W WO 2008045419 A1 WO2008045419 A1 WO 2008045419A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
aryl
methyl
process according
fluoro
Prior art date
Application number
PCT/US2007/021548
Other languages
French (fr)
Inventor
Steven D. Axt
Keshab Sarma
Justin Vitale
Jiang Zhu
Bruce Ross
Suguna Rachakonda
Qingwu Jin
Byoung-Kwon Chun
Original Assignee
Pharmasset, Inc.
F. Hoffmann La-Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK07839369.1T priority Critical patent/DK2084174T3/en
Priority to EP07839369.1A priority patent/EP2084174B1/en
Application filed by Pharmasset, Inc., F. Hoffmann La-Roche Ag filed Critical Pharmasset, Inc.
Priority to JP2009532372A priority patent/JP5252459B2/en
Priority to PL07839369T priority patent/PL2084174T3/en
Priority to US12/444,608 priority patent/US8912321B2/en
Priority to CN200780037855.XA priority patent/CN101600725B/en
Priority to ES07839369T priority patent/ES2429290T3/en
Priority to BRPI0719174A priority patent/BRPI0719174A2/en
Priority to KR1020097008991A priority patent/KR101057239B1/en
Priority to AU2007307057A priority patent/AU2007307057B2/en
Priority to SI200731311T priority patent/SI2084174T1/en
Priority to CA2666098A priority patent/CA2666098C/en
Priority to MX2009003795A priority patent/MX2009003795A/en
Publication of WO2008045419A1 publication Critical patent/WO2008045419A1/en
Priority to IL198086A priority patent/IL198086A/en
Priority to HK10101126.3A priority patent/HK1133889A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/02Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Abstract

The present process provides an improved method for the preparation of 4- amino-l-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl- tetrahydro-furan-2-yl)-lH-pyrimidin-2-one of the formula (IV) which is a potent inhibitor of Hepatitis C Virus (HCV) NS5B polymerase.

Description

PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES
This application is being filed on October 5, 2007, as a PCT International Patent application in the name of PHARMASSET, INC., a U.S. national corporation, and F. HOFFMANN LA-ROCHE AG, a Swiss national corporation, applicants for the designation of all countries except the US, and Steven D. Axt, U.S. citizen; Keshab Sarma, U.S. citizen; Justin Vitale, a U.S. citizen; Jiang Zhu, a
Canadian citizen; Bruce Ross, a U.S. citizen; Suguna Rachakonda, an Indian citizen; Qingwu Jin, a Chinese citizen; and Byoung-Kwon Chun, a Korean citizen; applicants for the designation of the US only, and claims priority to U.S. Provisional patent application Serial No. 60/850,962, filed October 10, 2006. The present invention relates to an improved process for the preparation of 4- amino-l-((2R,3R,4Rs5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3-methyl- tetrahydrofuran-2-yl)-lH-pyrimidin-2-one of the formula
Figure imgf000002_0001
which is a potent inhibitor of Hepatitis C Virus (HCV) NS5B polymerase.
The PCT Publication WO 2006/012440 discloses a process according to the scheme below. The process requires the burdensome separation of the anomers 14 and 16.
Figure imgf000003_0001
14 16 (18)
Object of the present invention is to provide an improved and scalable process for the preparation of 4-amino-l-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5- hydroxymethyl-3 -methyl-tetrahydro-fiiran-2-yl)-l H-pyrimidin-2-one of the formula
Figure imgf000003_0002
which avoids the drawbacks known in the art.
The process of the present invention comprises a) transforming an (aryl)alkanoic acid (2R,3R,4R)-2-
(aryl)alkanoyloxymethyl-4-fluoro-4-methyl-5-oxo-tetrahydro-furan-3-yl ester of formula II
Figure imgf000003_0003
(ID wherein R is aryl or alkyl into an (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro- 4-fluoro-4-methyl-tetrahydro-fimf n-3-yl ester of formula III
R(O=)C0- tCI
R(O=OCO V (HI)
wherein R is aryl or alkyl; b) converting the (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro-4-fluoro-4-methyl-tetrahydro-furan-3-yl ester of formula III into an(aryl)alkanoic acid (2RJ3R,4R,5R)-3-(aryl)alkanoyloxy-5-(4-benzoylamino-2- oxo-2Hpyrimidin-l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2-ylniethyI ester of formula I
Figure imgf000004_0001
(I) wherein R is aryl or alkyl and Bz is benzoyl and c) hydrolyzing the (aryl)alkanoic acid (2R,3R54R)5R)-3-(aryl)alkanoyloxy-5- (4-benzoylamino-2-oxo-2H-pyrimidm-l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2- ylmethyl ester of formula I to afford the 4-amino-l-((2R,3R,4R,5 5 R)-3-fluoro-4- hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-lH-pyrimidin-2-one of formula IV.
The term (aryl)alkanoic acid as used herein refers to a group RCO2H wherein R is either alkyl or aryl as those terms are defined herein. Correspondingly the term (aryl)alkanoic ester refers to a group RCO2R' where R is either alkyl or aryl. Most typically the R' represents the 3' and/or 51 position(s) of a ribose ring. The terms "(aryl)alkanoyl" and "(aryl)alkanoyloxy" refer to the groups RCO- and RCOO- respectively, where R is as described previously. The term "(aryl)alkanoyloxymethyl" group refers a group RCOOCH2- where R is as described previously.
The term "alkyl" as used herein denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms. The term "aryl" as used herein refers to phenyl group.
In a preferred embodiment of the present invention R has the meaning of phenyl.
In general, the nomenclature used in this Application is based on AUTONOM™ v.4.0, a Beilstein Institute computerized system for the generation of ITJPAC systematic nomenclature. If there is a discrepancy between a depicted structure- and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it. The transformation in step a) comprises a reduction in the presence of a reducing agent and a subsequent chlorination in the presence of chlorinating agent.
Suitable reducing agent is sodium έ/.y-(2-methoxyethoxy) (2,2,2- trifluoroethoxy) aluminum hydride which is commercially available under the tradename RedAl® as a solution in toluene. The reduction usually takes place in an organic solvent such as in a halogenated hydrocarbon like dichloromethane at a reaction temperature of below 00C, preferably below -5°C.
After completion of the reduction the reaction mixture is subjected to the chlorination reaction. The chlorinating agent is as a rule selected from sulfuryl chloride, thionyl chloride or phosphorus oxychloride.
Preferably sulfuryl chloride in the presence of catalytic amounts of tetrabutyl ammonium bromide is used.
The chlorination is expediently performed at a reaction temperature between 00C and 400C.
The (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro-4- fluoro-4-methyl-tetrahydro-furan-3-yl ester of formula III can be separated from the reaction mixture applying techniques known to the skilled in the art.
The conversion in step b) comprises reacting the (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxymethyl-5-chloro-4-fluoro-4-methyl-tetrahydro- furan-3-yl ester of formula III with O-trimethyl silyl-N4-benzoylcytosin in the presence of a Lewis acid.
The O-trimethyl silyl-N4-benzoylcytosin may be prepared in situ by reacting N-benzoyl cytosine with hexamethyldisilazan in the presence of ammonium sulfate in chlorobenzene under reflux conditions.
Common Lewis acids known in the art are suitable for the conversion in step b). Good results have been achieved with stannic chloride.
The reaction is usually performed at elevated temperature, for instance at about 70°C until the coupling is complete.
The (aryl)alkanoic acid (2R,3R,4R,5R)-3-(aryl)alkanoyloxy-5-(4- , benzoylammo-2-oxo-2H-ρyrimidin-l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2- ylmethyl ester of formula I so obtained can be separated from the reaction mixture applying techniques known to the skilled in the art. The hydrolysis in step c) is performed in the presence of a base.
Suitable bases are organic bases like alkali metal alkoxides. Preferably sodium methoxide in methanol as solvent is used.
The reaction is performed at elevated temperature, for instance at about 500C until the hydrolysis is complete. The 4-amino-l-((2RJ3R,4R,5R)-3-fluoro-4-hydroxy-5-hydroxymethyl-3- methyltetrahydro-furan-2-yl)-lH-pyrimidin-2-one of the formula IV can be isolated following methods known to the skilled in the art.
In a further embodiment of the present invention a process for the preparation of the starting product, the (aryl)alkanoic acid (2R,3R,4R)-2- (aryl)alkanoyloxymethyl-4-fluoro-4-methyl-5-oxo-tetrahydro-furan-3-yl ester of formula II
Figure imgf000006_0001
(H) wherein R is phenyl has been developed. The process comprises the steps al) transforming the (E)-3-((S)-2,2-dimethyl-[l,3]dioxolan-4-yl)-2-methyl- acrylic acid ethyl ester of formula V
Figure imgf000007_0001
(V)
into the (2S,3R)-3-((R)-2,2-dimethyl-[ 1 ,3]dioxolan-4-yl)-2,3-dihydroxy-2- methyl propionic acid ethyl ester of formula VI
Figure imgf000007_0002
(Vl)
bl) converting the (2S,3R)-3-((R)-2,2-dimethyl-[l33]dioxolan-4-yl)-2J3- dihydroxy-2-methyl-propionic acid ethyl ester of formula VI into the sulfite of formula VII
Figure imgf000007_0003
cl) further reacting the sulfite of formula VII to the sulfate of formula VIII
Figure imgf000008_0001
dl) transforming the sulfate of formula VIII into the fluorohydrin sulfate of formula IX
Figure imgf000008_0002
el) decomposing the fluorohydrin sulfate of formula IX into the lactone of formula X
Figure imgf000008_0003
(X)
and finally fl) acylating the lactone of formula X to form the end product of formula II wherein R is phenyl. The present process can be described with SCHEME A below:
Figure imgf000009_0001
(al) acetone-NaMnO4 (aq), ethylene glycol, NaHCO3, -10 to 00C; aq. NaHSO3 (quench); (bl) i-PrOAc, MeCN, TEA, SOCl2; (cl) i-PrOAc, MeCN, NaOCl; (dl) TEA-3HF, TEA; (el) HCl (aq)-BaCl2-aq; (fl) (PhCO) 2O, DMAP, MeCN.
The asymmetric hydroxylation in step al) was discovered to be best carried out with sodium permanganate in the presence of ethylene glycol, sodium bicarbonate in acetone at a temperature of -20 to 0° C which afforded the diol in 60-64% on pilot plant scale. Starting compound (V) can be obtained from (lS,2S)-l,2-όz>((R)-2,2-dimethyl-[l,3]dioxolan-4-yl)-ethane- 1,2-diol (C. R. Schmid and J. D. Bryant, Jerry D., Org. Syn. 1995 72:6-13) by oxidative cleavage of the diol and treating the resulting aldehyde with 2- (triphenyl-λ5-phosphanylidene)-propionic acid ethyl ester.
The cyclic sulfate (VIII) can be prepared by cyclization of the vicinal diol with e.g. thionyl chloride in step bl) and oxidation of the resulting cyclic sulfite (VII) in step cl) to the corresponding sulfate (VIII) with NaOCl in the presence of MeCN. It has been found that the cyclic sulfates can be stabilized during processing by the addition of a trialkylamine such as TEA or DIPEA at 2-10 mole % relative to the cyclic sulfate. Differential scanning calorimetry (DSC) showed a shift in the onset of decomposition from approximately 110 to 180 0C when 3.5 mole % of DIPEA was added to (VIII). Contacting (VIII) with triethylamine-trihydrofluoride/TEA in step dl) affords the sulfated fluorohydrin (IX) which in the presence of water affords the fluorohyrin (X) An improved yield of (X) can be obtained in step dl) when BaCl2 is incorporated in the reaction mixture to scavenge the liberated sulfate. Under the acidic conditions concomitant hydrolysis of the acetonide liberates a triol which spontaneously cyclizes to the γ-lactone (X). Contacting (X) with benzoic anhydride and DMAP in step fl) affords the dibenzoate of the lactone (lib) which is used in the glycosylation step. While the benzoyl protecting group (R=phenyl) is preferred, other potential protecting groups selected from methoxymethyl, methoxyethyl, benzyloxymethyl, ethoxymethyl, trityl, triethylsilyl, t-butyldimethylsilyl, t- butyldiphenylsilyl, acyl including acetyl, pivaloyl. benzoyl, toluoyl, 4-phenyl benzoyl, 2-, 3-, or 4-nitrobenzoyl, 2-, 3-, or 4-chlorobenzoyl, other substituted benzoyl may be applied. The base used for step fl) includes, but is not limited to the following list: imidazole, pyridine, DMAP, TEA, DIPEA, l,4-diazabicyclo[2,2,2]octane. The solvent used for step fl) includes, but is not limited to acetonitrile, pyridine, DCM, chloroform, DCE, THF.
Examples
The abbreviations used include: 1,2-dichloroethane (DCE), dichloromethane (DCM), di-iso-propylethylamine (DIPEA), N,N-dimethyl acetamide (DMA), 4-N,N-dimethylaminopyridine (DMAP), ethanol (EtOH), ethylacetate (EtOAc), methanol (MeOH), methyl (Me), ethyl (Et), isopropanol (IPA), acetonitrile 5 (MeCN), phenyl (Ph), room temperature (rt or RT), triethylamine (TEA or Et3N), tetrahydrofuran (THF).
Example 1 Benzoic acid 3-benzoyloxy-5-(4-benzoylamino-2-oxo-2H-pyrimidin- l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2-yhnethyl ester (14)
Figure imgf000011_0001
Trifluoroethanol (4.08 kg) is added slowly to a cold solution (-150C) of RED-AL® solution (12.53 kg) and toluene (21.3 kg) while maintaining the reaction temperature at or below -100C. After warming up to ambient temperature (ca. 200C), the modified RED-AL reagent mixture (30.1 kg out of the 37.6 kg prepared) is added slowly to a pre-cooled solution (-150C) of fluorolactone dibenzoate 10 (10 kg) in DCM (94.7 kg) while maintaining reaction temperature at or below -100C. After reduction of the lactone (monitored by in-process HPLC)5 catalytic amounts of tetrabutylammonium bromide (90 g) is added to the reaction mixture. Sulfuryl chloride (11.86 kg) is then added while maintaining reaction temperature at or below 00C. The reaction mixture is then heated to 400C until formation of the chloride is complete (ca. 4 h) or warmed to ambient temperature (20-250C) and stirred over night (ca 16 h). The reaction mixture is cooled to about 00C, and water (100 L) is added cautiously while maintaining reaction temperature at or below 15°C. The reaction mixture is then stirred at ambient temperature for ca 1 h to ensure hydrolytic decomposition of excess sulfuryl chloride and the phases are separated. The organic layer is washed with a dilute solution of citric acid (prepared by dissolving 15.5 kg of citric acid in 85 L of water) and then with dilute KOH solution (prepared by dissolving 15 kg of 50% KOH in
100 L of water). The organic phase is then concentrated and solvents are replaced with chlorobenzene (2 x 150 kg) via atmospheric replacement distillation. The resulting solution containing 30 is dried azeotropically. A suspension of N-benzoyl cytosine (8.85 kg), ammonium sulfate (0.07 kg) and hexamethyldisilazane (6.6 kg) in chlorobenzene (52.4 kg) is heated to reflux (ca. 135°C) and stirred (ca. 1 h) until the mixture becomes a clear solution. The reaction mixture is then concentrated in vacuo to obtain the O-trimethyl silyl-N4-benzoylcytosin as a syrupy liquid. The anhydrous solution of 30 in chlorobenzene (as prepared) and stannic chloride (28.2 kg) are added to this concentrate. The reaction mixture is maintained at about 700C until the desired coupling reaction is complete (ca. 10 h) as determined by in process HPLC. Upon completion, the reaction mixture is cooled to ambient temperature and diluted with DCM (121 kg). This solution is added to a suspension of solid NaHCO3 (47 kg) and CELITE® (9.4 kg) in DCM
(100.6 kg). The resulting slurry is cooled to 10-150C, and water (8.4 kg) is added slowly to quench the reaction mixture. The resulting suspension is very slowly (caution: gas evolution) heated to reflux (ca. 45°C) and maintained for about 30 min. The slurry is then cooled to ca. 15°C, and filtered. The filter cake is repeatedly reslurried in DCM (4 x 100 L) and filtered. The combined filtrate is concentrated under atmospheric pressure (the distillate collected in the process is used for reslurrying the filter cake) until the batch temperature rises to about 900C and then allowed to cool slowly to about -5°C. The resulting slurry is aged for at least 2 h at -5°C. The precipitated product is filtered and washed with IPA (30 kg + 20 kg), and oven-dried in vacuo at about 700C to afford 8.8 kg (57.3%) of l-(2- deoxy-2-fluoro-2-methyl-3-5-Odibenzoyl-j8-D-ribofuranosyl)-N-4- benzoylcytosine (14, CAS Reg No. 817204-32-3) which was 99.3% pure.=
Example 2
4-Amino-l-(3-fiuoro-4-hydroxy-5-hydroxymethyl-3-methyl- tetrahydro-furan-2-yl)-lH-pyrimidin- 2-one (18)
Figure imgf000012_0001
14 18
A slurry of 14 (14.7 kg) in MeOH (92.6 kg) is treated with catalytic amounts of methanolic sodium methoxide (0.275 kg). The reaction mixture is heated to ca. 500C and aged (ca 1 h) until the hydrolysis is complete. The reaction mixture is quenched by addition of isobutyric acid (0.115 kg). The resulting solution is concentrated under moderate vacuum and then residual solvents are replaced with IPA (80 kg). The batch is distilled to a volume of ca. 50 L. The resulting slurry is heated to ca. 800C and then cooled slowly to ca. 5°C and aged (ca. 2 h). The precipitated product is isolated by filtration, washed with IPA (16.8 kg) and dried in an oven at 700C in vacuo to afford 6.26 kg (88.9%) of 18 which assayed at 99.43% pure
Example 3
(2S,3R)-3-[(4R)-2,2-dimemyl-[l,3] dioxolan-4-yl]-2,3-dϊhydroxy-2- methyl-propionic acid ethyl ester (24)
Figure imgf000013_0001
A suspension of 22 (10 kg, CAS Reg. No. 81997-76-4), ethylene glycol (11.6 kg), solid NaHCO3 (11.8 kg) and acetone (150 L) is cooled to ca. -15° C. A solution of 36% aqueous NaMnO4 (19.5 kg) is charged slowly (over 4 h) to the suspension maintaining reaction temperature at or below -100C. After stirring for 0.5 h at -10° C, an aliquot of the reaction mixture (ca. 5 mL) is quenched with 25% aqueous sodium bisulfite (ca. 15 mL). A portion of resulting slurry is filtered and submitted for GC analysis to check the progress of the reaction. When the reaction is complete, the reaction mixture is quenched by slow (over 40 min) addition of cooled (ca. 00C) 25% aqueous NaHSCb (60 L). The temperature of the reaction mixture is allowed to reach 4°C during the quench. CELITE® (ca. 2.5 kg) is then slurried in acetone (8 kg) and added to the dark brown reaction mixture. The resulting slurry is aged at ambient temperature to obtain light tan slurry. The slurry is filtered, and the filter cake is washed with acetone (3 x 39 kg). The combined filtrate is concentrated by vacuum distillation (vacuum approximately 24 inches of Hg (ca. 810 mbar); max pot temperature is 32°C) to remove the acetone. The aqueous concentrate is extracted with EtOAc (3 x 27 kg), and the combined organic extracts were washed with water (25 L). The organic phase is then concentrated by atmospheric distillation and EtOAc is replaced with toluene. The volume of the batch is adjusted to ca. 20 L. Heptane (62 kg) is added and the batch cooled to ca. 27° C to initiate crystallization. The batch is then cooled to -10° C. After aging overnight at -10° C5 the product is filtered, washed with 10% toluene in heptane and dried at 500C under vacuum to afford 6.91 kg (59.5%) of 24 (CA RN 81997-76-4) as a white crystalline solid.
Example 4
(3R,4R,5R)-3-Fluoro-4-hydroxy-5-hydroxymethyl-3-methyl-dihydro- furan-2-one (10)
Figure imgf000014_0001
step i 24: R = R* = H 38 S sltBeDpd 4 I |_^ 2 10 8: : R R".. = - cHoph step 2 1 -36: R, R" = SO 26: R, R* = SO2
Steps 1 & 2 - A dry, clean vessel was charged with 24 (6.0 kg), isopropyl acetate (28.0 kg), MeCN (3.8 kg) and TEA (5.4 kg). The mixture was cooled to 5-100C, and thionyl 10 chloride (3.2 kg) was added slowly while cooling the solution to maintain the temperature below 200C. The mixture was stirred until no starting material was left (GC analysis). The reaction was typically complete within 30 min after addition is complete. To the mixture was added water (9 kg) and after stirring, the mixture was allowed to settle. The aqueous phase was discarded and the organic phase was washed with a mixture of water (8 kg) and saturated NaHCO3 (4 kg ) solution. To the remaining organic phase containing 36 was added MeCN (2.5 kg ) and solid NaHCO3 (3.1 kg). The resulting slurry was cooled to ca. 100C. Bleach (NaOCl solution, 6.89 wt% aqueous solution, 52.4 kg, 2 eq.) was added slowly while cooling to maintain temperature below 25°C. The mixture was aged with stirring over 90-120 min at 20-250C, until the reaction was complete (GC analysis). After completion of the reaction, the mixture was cooled to ca. 100C and then quenched with aqueous Na2SO3 solution (15.1% w/w, 21 kg) while cooling to maintain temperature below 200C. The quenched reaction mixture was filtered through a cartridge filter to remove inorganic solids. The filtrate was allowed to settle, and phases are separated and the aqueous phase is discarded. The organic layer was washed first with a mixture of water (11 kg ) and saturated NaHCO3 solution (4.7 kg), then with of saturated NaHCO3 solution (5.1 kg). DIPEA (220 mL) was added to the organic phase and the resulting solution was filtered through CELITE® (bag filter) into a clean drum. The reactor was rinsed with isopropyl acetate (7 kg) and the rinse is transferred to the drum. The organic phase was then concentrated under vacuum ca. 850-950 mbar while maintaining reactor jacket temperature at 45-50°C to afford 26 as an oil (~10 L). Additional
DIPEA (280 mL) .was added and the vacuum distillation was continued (jacket temperature 50-550C) until no more distillate was collected. (Batch volume ca. 7 L).
Step 3 - To the concentrated oil from step 2 containing 26 was 5 added TEA
(2.34 kg )and TEA-trihydrofluoride (1.63 kg). The mixture was heated to 85°C for 2 h. The batch was sampled to monitor the progress of the reaction by GC. After the reaction was complete cone. HCl (2.35 kg) was added to the mixture and the resulting mixture heated to ca. 90° C (small amount of distillate collected). The reaction mixture was stirred at ca. 90° C for 30 min and then saturated aqueous BaCl2 solution (18.8 kg) was added. The resulting suspension was stirred at about 900C for 4 h. The resulting mixture was then azeotropically dried under a vacuum (9-10 inches of Hg) by adding slowly n-propanol (119 kg ) while distilling off the azeotropic mixture (internal batch temperature ca. 85-900C). To the residual suspension was added toluene (33 kg ) and vacuum distillation was continued to distill off residual n-propanol (and traces of water) to a minimum volume to afford 28.
Step 4 - To the residue from step 3 containing 28 was added MeCN (35 kg) and ca. 15L was distilled out under atmospheric pressure. The reaction mixture was cooled to ca. 100C and then benzoyl chloride (8.27 kg) and DMAP (0.14 kg) are added. TEA (5.84 kg) was added slowly to the reaction mixture while cooling to maintain temperature below 4O0C. The batch was aged at ca. 200C and the progress of the benzoylation is monitored by HPLC. After completion of the reaction, EtOAc (30 kg) was added to the mixture and the resulting suspension is stirred for about 30 min. The reaction mixture was filtered through a CELITE® pad (using a nutsche filter) to remove inorganic salts. The solid cake was washed with EtOAc (38 kg). The combined filtrate and washes were washed successively with water (38 kg), saturated NaHCθ3 solution (40 kg) and saturated brine (44 kg). The organic phase was polish-filtered (through a cartridge filter) and concentrated under modest vacuum to minimum volume. IPA (77 kg) was added to the concentrate and ca. 25 L of distillate was collected under modest vacuum allowing the infernal batch temperature to reach ca 75°C at the end of the distillation. The remaining solution was then cooled to ca. 5°C over 5 h and optionally aged overnight. The precipitate was filtered and washed with of cold (ca. 5°C) IPA (24 kg). The product was dried under vacuum at 60-700C to afford 6.63 kg (70.7% theory of 10 which was 98.2% pure by HPLC.

Claims

Claims
1. A process for the preparation of 4-amino-l-((2R,3R,4R,5R)-3-fluoro-4- hydroxy-5-hydroxymethyl-3-methyl-te1rahydro-ruran-2-yl)-lH-pyrimidin-2-one of formula
Figure imgf000017_0001
compπsing a) transforming an (aryl)alkanoic acid (2R,3R,4R)-2-
(aryl)alkanoyloxymethyl-4- fluoro-4-methyl-5-oxo-tetrahydro-furan-3-yl ester of formula II
Figure imgf000017_0002
(H)
wherein R is aryl or alkyl into an (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro- 4-fluoro-4-methyl-tetrahydro-furan-3-yl ester of formula III
Figure imgf000017_0003
(III)
wherein R is aryl or alkyl; b) converting the (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro-4-fluoro-4-methyl-tetrahydro-furan-3-yl ester of formula III into an (aryl)alkanoic acid (2R,3R,4R,5R)-3-(aryl)alkanoyloxy-5-(4-benzoylamino-2-oxo- 2H-pyrimidin-l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2-ylmethyl ester of formula I
Figure imgf000018_0001
(I)
wherein R is aryl or alkyl and Bz is benzoyl and c) hydrolyzing the (aryl)alkanoic acid (2R,3R,4R,5R)-3-(aryl)alkanoyloxy-5- (4-benzoylamino-2-oxo-2H-pyrimidin-l-yl)-4-fluoro-4-methyl-tetrahydro-furan-2- ylmethyl ester of formula I to afford the 4-amino-l-((2R,3R,4R)5 5 R)-3-fluoro-4- hydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)- 1 H-pyrimidin-2-one of formula IV
2. Process according to claim 1, characterized in that R has the meaning of phenyl.
3. Process according to claim 1 or 2, characterized in that the transformation in step a) comprises a reduction in the presence of a reducing agent and a subsequent chlorination in the presence of chlorinating agent.
4. Process according to claim 3, characterized in that the reducing agent is sodium bis-(2-methoxyethoxy)(2,2,2-trifluoro-ethoxy)aluminum hydride
5. Process according to claim 3, characterized in that the chlorinating agent is selected form sulfuryl chloride, thionyl chloride or phosphorus oxychloride
6. Process according to claim 5, characterized in that the chlorinating agent is sulfuryl chloride in the presence of catalytic amounts of tetrabutylammonium bromide.
7. Process according to claim 1 or 2, characterized in that the conversion in step b) comprises reacting the (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxy methyl-5-chloro-4-fluoro-4-methyl-tetrahydro-ftιran-3-yl ester of formula III with O-trimethyl silyl-N4-benzoylcytosin in the presence of a Lewis acid.
8. Process according to claim 1 or 2, characterized in that the hydrolysis in step c) is performed in the presence of a base.
9. Process according to claim 1, comprising the preparation of an (aryl)alkanoic acid (2R,3R,4R)-2-(aryl)alkanoyloxymethyl-4-fluoro-4-methyl-5- oxo-tetrahydro-furan-3-yl ester of formula II
Figure imgf000019_0001
CII)
wherein R is phenyl, comprising the steps of al) transforming the (E)-3-((S)-2,2-dimethyl-[l,3]dioxolan-4-yl)-2-methyl-acrylic acid ethyl ester of formula V
CV)
into the (2S,3R)-3-((R)-2,2-dimethyl-[l ,3]dioxolan-4-yl)-2,3-dihydroxy-2- methylpropionic acid ethyl ester of formula VI
Figure imgf000020_0001
(Vl)
bl) converting the (2S,3R)-3-((R)-2,2-dimethyl-[l,3]dioxolan-4-yl)-2,3-dihydroxy- 2-methyl-propionic acid ethyl ester of formula VI into the sulfite of formula VII
Figure imgf000020_0002
cl) further reacting the sulfite of formula VII to the sulfate of formula VIII
Figure imgf000020_0003
dl) transforming the sulfate of formula VIII into the fluorohydrin sulfate of formula IX
Figure imgf000020_0004
(IX)
el) decomposing the fluorohydrin sulfate of formula IX into the lactone of formula X
Figure imgf000021_0001
(X)
and finally fl) acylating the lactone of formula X to form the end product of formula II wherein
R is phenyl
-
10. Process according to claim 9, characterized in that the transformation in step al) is performed with sodium permanganate in the presence of ethylene glycol and sodium bicarbonate.
11. Process according to claim 9, characterized in that the transformation in step bl) is performed with thionylchloride.
12. Process according to claim 9, characterized in that the transformation in step cl) is performed with sodium hypochlorite.
13. Process according to claim 9, characterized in that the transformation in step dl) is performed with a trialkylamine.14. Process according to claim 13, characterized in that triethylamine together with triethylamin-trihydrofluoride is used.15. Process according to claim 9, characterized in that the decomposition in step el) is performed with barium chloride in water.16. Process according to claim 9, characterized in that the acylation 5 in step fl) is performed with benzoic anhydride.17. The process as hereinbefore described.
PCT/US2007/021548 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines WO2008045419A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
KR1020097008991A KR101057239B1 (en) 2006-10-10 2007-10-05 Preparation of Nucleoside Ribofuranosyl Pyrimidine
BRPI0719174A BRPI0719174A2 (en) 2006-10-10 2007-10-05 preparation of ribofuranosyl nucleoside pyrimidines
JP2009532372A JP5252459B2 (en) 2006-10-10 2007-10-05 Preparation of ribofuranosylpyrimidine nucleosides
EP07839369.1A EP2084174B1 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
US12/444,608 US8912321B2 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
CN200780037855.XA CN101600725B (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
AU2007307057A AU2007307057B2 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
DK07839369.1T DK2084174T3 (en) 2006-10-10 2007-10-05 Preparation of ribofuranosylpyrimidine nucleotides
PL07839369T PL2084174T3 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
ES07839369T ES2429290T3 (en) 2006-10-10 2007-10-05 Preparation of ribofuranosylpyrimidine nucleosides
SI200731311T SI2084174T1 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
CA2666098A CA2666098C (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines
MX2009003795A MX2009003795A (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines.
IL198086A IL198086A (en) 2006-10-10 2009-04-07 Preparation of nucleosides ribofuranosyl pyrimidines
HK10101126.3A HK1133889A1 (en) 2006-10-10 2010-02-02 Preparation of nucleosides ribofuranosyl pyrimidines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85096206P 2006-10-10 2006-10-10
US60/850,962 2006-10-10

Publications (1)

Publication Number Publication Date
WO2008045419A1 true WO2008045419A1 (en) 2008-04-17

Family

ID=39111500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021548 WO2008045419A1 (en) 2006-10-10 2007-10-05 Preparation of nucleosides ribofuranosyl pyrimidines

Country Status (19)

Country Link
US (2) US8912321B2 (en)
EP (1) EP2084174B1 (en)
JP (1) JP5252459B2 (en)
KR (1) KR101057239B1 (en)
CN (1) CN101600725B (en)
AU (1) AU2007307057B2 (en)
BR (1) BRPI0719174A2 (en)
CA (1) CA2666098C (en)
DK (1) DK2084174T3 (en)
ES (1) ES2429290T3 (en)
GT (1) GT200900080A (en)
HK (1) HK1133889A1 (en)
IL (1) IL198086A (en)
MX (1) MX2009003795A (en)
PL (1) PL2084174T3 (en)
PT (1) PT2084174E (en)
RU (1) RU2421461C2 (en)
SI (1) SI2084174T1 (en)
WO (1) WO2008045419A1 (en)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
WO2010135569A1 (en) 2009-05-20 2010-11-25 Pharmasset, Inc. N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
WO2011152155A1 (en) 2010-06-03 2011-12-08 セントラル硝子株式会社 Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-γ-lactone precursor
EP2609923A2 (en) 2010-03-31 2013-07-03 Gilead Pharmasset LLC Nucleoside Phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US8580765B2 (en) 2007-03-30 2013-11-12 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
WO2013178571A1 (en) 2012-05-29 2013-12-05 F. Hoffmann-La Roche Ag Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8759510B2 (en) 2008-06-11 2014-06-24 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CN104610404A (en) * 2015-01-16 2015-05-13 南通常佑药业科技有限公司 Preparation method of ribofuranose phosphate derivative
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
US9376410B2 (en) 2012-10-10 2016-06-28 Topharman Shanghai Co., Ltd. (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
ES2726998T3 (en) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Modified fluorinated nucleoside analogs
PT3109244T (en) * 2004-09-14 2019-06-04 Gilead Pharmasset Llc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
KR101229942B1 (en) 2004-11-16 2013-02-06 톰슨 라이센싱 Film grain sei message insertion for bit-accurate simulation in a video system
ATE553455T1 (en) 2004-11-16 2012-04-15 Thomson Licensing METHOD FOR SIMULATING FILM GRAIN BASED ON PRECALCULATED TRANSFORMATION COEFFICIENTS
TR201911138T4 (en) 2004-11-17 2019-08-21 Interdigital Vc Holdings Inc Bit-free film grain simulation method based on pre-computed transformed coefficients.
US10715834B2 (en) 2007-05-10 2020-07-14 Interdigital Vc Holdings, Inc. Film grain simulation based on pre-computed transform coefficients
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
EP2755983B1 (en) 2011-09-12 2017-03-15 Idenix Pharmaceuticals LLC. Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EA201490836A1 (en) 2011-10-21 2014-11-28 Эббви Инк. COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
AU2013266393B2 (en) 2012-05-22 2017-09-28 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
EA027929B1 (en) 2012-05-25 2017-09-29 Янссен Сайенсиз Айрлэнд Юси Uracyl spirooxetane nucleosides
CN103450148B (en) * 2012-06-04 2018-06-12 浙江九洲药业股份有限公司 A kind of synthetic method of five-membered ring sulfate compound
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
ES2674980T3 (en) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc 2'-chloro nucleoside analogs for HCV infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
CN103012386B (en) * 2012-12-26 2015-04-01 浙江普洛得邦制药有限公司 Preparation method of five-membered cyclic sulphate
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
EP3027636B1 (en) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN104447923B (en) * 2013-09-23 2018-03-30 中国药科大学 Methyl nucleoside derivatives of 2 ' deoxidation, 2 ' fluorine 2 ' and preparation method thereof and the purposes in pharmacy
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN104744539A (en) * 2014-09-19 2015-07-01 上海皓元生物医药科技有限公司 Synthesis method for (2'R)-2'-deoxy-2'-fluorine-2'-methyl uridine
CN104327138B (en) * 2014-10-21 2017-05-10 齐鲁制药有限公司 Preparation method of PSI-7977 intermediate compound
UA124966C2 (en) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N<sup>6</sup>-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
CN104829672B (en) * 2015-05-19 2018-03-13 江苏福瑞生物医药有限公司 A kind of synthetic method of pharmaceutical intermediate
CN105061535A (en) * 2015-09-02 2015-11-18 江苏科本医药化学有限公司 Synthetic method of sofosbuvir intermediate
CN106554333B (en) * 2015-09-29 2018-11-30 江苏福瑞生物医药有限公司 A kind of synthetic method of pharmaceutical intermediate
CN106608896B (en) * 2015-10-26 2019-08-27 江苏福瑞康泰药业有限公司 A kind of synthetic method of pharmaceutical intermediate
CN105418547A (en) * 2015-11-17 2016-03-23 海门慧聚药业有限公司 Preparation for sofosbuvir key intermediate
CN105503983B (en) * 2015-12-17 2019-06-28 江苏阿尔法药业有限公司 The preparation method of Suo Feibuwei intermediate and its derivative
CN105566422B (en) * 2015-12-29 2019-06-25 江苏阿尔法药业有限公司 The preparation method of Suo Feibuwei intermediate or derivatives thereof
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
KR20230151050A (en) 2017-02-01 2023-10-31 아테아 파마슈티컬즈, 인크. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN106810515A (en) * 2017-02-06 2017-06-09 抚州市星辰药业有限公司 The midbody compound and its synthetic method of a kind of synthesis Suo Feibuwei
CN109422789A (en) * 2017-08-28 2019-03-05 常州制药厂有限公司 A kind of preparation process amelioration method of Suo Feibuwei
TW202012001A (en) 2018-04-10 2020-04-01 美商亞堤製藥公司 Treatment of cirrhotic hcv infected patients
CN108675984A (en) * 2018-06-22 2018-10-19 江苏阿尔法药业有限公司 The preparation method of Suo Feibuwei intermediates
CN111606961A (en) * 2019-02-26 2020-09-01 顾世海 Process production method of (2 'R) -2' -deoxy-2 '-fluoro-2' -methyluridine
CN111040010A (en) * 2019-12-23 2020-04-21 上海红蓝医药科技有限公司 Synthetic method of sofosbuvir intermediate
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (en) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Production of cytidine derivatives
US20050009737A1 (en) * 2003-05-30 2005-01-13 Jeremy Clark Modified fluorinated nucleoside analogues
WO2006012440A2 (en) * 2004-07-21 2006-02-02 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE344271T1 (en) 1998-02-25 2006-11-15 Univ Emory 2'-FLUORONUCLEOSIDES
IL147757A0 (en) 1999-07-30 2002-08-14 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (en) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед APPLICATION OF RIBONOUSALIC COMPOUNDS FOR TREATING FLAVIVIRUS AND PESTIVIRUS INFECTIONS
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
JP2005504087A (en) 2001-09-28 2005-02-10 イデニクス(ケイマン)リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
BR0312278A (en) 2002-06-28 2007-06-19 Idenix Cayman Ltd 2'-c-methyl-3'-o-1-valine ribofuranosyl cytidine ester for treatment of flaviviridae infections
JP2005533817A (en) 2002-06-28 2005-11-10 イデニクス(ケイマン)リミテツド Modified 2 'and 3'-nucleoside prodrugs for the treatment of Flaviviridae virus infection
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
BRPI0412849A (en) 2003-07-25 2006-09-26 Idenix Cayman Ltd compounds, compositions and uses of purine nucleoside analogues for the treatment of flaviviridae, including hepatitis c
JP2007504152A (en) 2003-08-27 2007-03-01 ビオタ, インコーポレイテッド Novel tricyclic nucleosides or nucleotides as therapeutic agents
CA2565013C (en) * 2004-04-30 2013-01-08 Daiichi Pharmaceutical Co., Ltd. Method for producing pentacyclic taxans

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0136693A2 (en) * 1983-10-03 1985-04-10 Takeda Chemical Industries, Ltd. Production of cytidine derivatives
US20050009737A1 (en) * 2003-05-30 2005-01-13 Jeremy Clark Modified fluorinated nucleoside analogues
WO2006012440A2 (en) * 2004-07-21 2006-02-02 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
WO2006031725A2 (en) * 2004-09-14 2006-03-23 Pharmasset, Inc. Preparation of 2'­fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. R. SCHMID; J. D. BRYANT; JERRY D., ORG. SYN., vol. 72, 1995, pages 6 - 13
HELMUT VORBRÜGGEN: "Adventures in Silicon-Organic Chemistry", ACCOUNTS OF CHEMICAL RESEARCH, vol. 28, 1995, pages 509 - 520, XP002471456 *

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580765B2 (en) 2007-03-30 2013-11-12 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8735372B2 (en) 2007-03-30 2014-05-27 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US11642361B2 (en) 2007-03-30 2023-05-09 Gilead Sciences, Inc. Nucleoside phosphoramidate prodrugs
US10183037B2 (en) 2007-03-30 2019-01-22 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9585906B2 (en) 2007-03-30 2017-03-07 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9085573B2 (en) 2007-03-30 2015-07-21 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8906880B2 (en) 2007-03-30 2014-12-09 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8759510B2 (en) 2008-06-11 2014-06-24 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP3222628A1 (en) 2008-12-23 2017-09-27 Gilead Pharmasset LLC Nucleoside phosphoramidates
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EA019295B1 (en) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Synthesis of purine nucleosides and process for preparing them
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8957045B2 (en) 2008-12-23 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2910562A1 (en) 2009-05-20 2015-08-26 Gilead Pharmasset LLC N-[(2'r)-2'-deoxy-2 '-fluoro-2'-methyl-p-phenyl-5 '-uridylyl]-l-alanine 1-methylethyl ester in crystalline form
US8642756B2 (en) 2009-05-20 2014-02-04 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8735569B2 (en) 2009-05-20 2014-05-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8633309B2 (en) 2009-05-20 2014-01-21 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8629263B2 (en) 2009-05-20 2014-01-14 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010135569A1 (en) 2009-05-20 2010-11-25 Pharmasset, Inc. N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
EP3321275A1 (en) 2009-05-20 2018-05-16 Gilead Pharmasset LLC Crystalline form of sofosbuvir
US9637512B2 (en) 2009-05-20 2017-05-02 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9284342B2 (en) 2009-05-20 2016-03-15 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9206217B2 (en) 2009-05-20 2015-12-08 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2913337A1 (en) 2009-05-20 2015-09-02 Gilead Pharmasset LLC N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production
EP2610264A2 (en) 2009-05-20 2013-07-03 Gilead Pharmasset LLC N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production
EP3290428A1 (en) 2010-03-31 2018-03-07 Gilead Pharmasset LLC Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
EP2752422A1 (en) 2010-03-31 2014-07-09 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
EP2609923A2 (en) 2010-03-31 2013-07-03 Gilead Pharmasset LLC Nucleoside Phosphoramidates
WO2011123645A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Nucleoside phosphoramidates
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
WO2011152155A1 (en) 2010-06-03 2011-12-08 セントラル硝子株式会社 Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-γ-lactone precursor
JP2012144511A (en) * 2010-06-03 2012-08-02 Central Glass Co Ltd METHOD FOR PRODUCING (2R)-2-FLUORO-2-C-METHYL-D-RIBONO-γ-LACTONE PRECURSOR
US8669382B2 (en) 2010-06-03 2014-03-11 Central Glass Company, Limited Method for producing (2R)-2-fluoro-2-C-methyl-D-ribono-γ-lactone precursor
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US10456414B2 (en) 2011-09-16 2019-10-29 Gilead Pharmasset Llc Methods for treating HCV
US9393256B2 (en) 2011-09-16 2016-07-19 Gilead Pharmasset Llc Methods for treating HCV
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013178571A1 (en) 2012-05-29 2013-12-05 F. Hoffmann-La Roche Ag Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
US9376410B2 (en) 2012-10-10 2016-06-28 Topharman Shanghai Co., Ltd. (2R)-2-deoxy-2,2-disubstituted-ribono-1,4-lactone and preparation method and use thereof
US10039779B2 (en) 2013-01-31 2018-08-07 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US11707479B2 (en) 2013-08-27 2023-07-25 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2016042576A1 (en) 2014-09-16 2016-03-24 Cadila Healthcare Limited Co-crystal of sofosbuvir and amino acid and process for preparation thereof
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104610404A (en) * 2015-01-16 2015-05-13 南通常佑药业科技有限公司 Preparation method of ribofuranose phosphate derivative
WO2016112746A1 (en) * 2015-01-16 2016-07-21 南通常佑药业科技有限公司 Method for preparing ribofuranose phosphate derivatives
US10239910B2 (en) 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir

Also Published As

Publication number Publication date
US8912321B2 (en) 2014-12-16
PL2084174T3 (en) 2013-12-31
GT200900080A (en) 2012-04-10
RU2009117396A (en) 2010-11-20
BRPI0719174A2 (en) 2017-06-13
US20080139802A1 (en) 2008-06-12
EP2084174A1 (en) 2009-08-05
JP2010505954A (en) 2010-02-25
CA2666098C (en) 2012-09-25
CA2666098A1 (en) 2008-04-17
MX2009003795A (en) 2009-06-18
JP5252459B2 (en) 2013-07-31
KR20090060460A (en) 2009-06-12
SI2084174T1 (en) 2013-10-30
EP2084174B1 (en) 2013-07-31
ES2429290T3 (en) 2013-11-14
CN101600725B (en) 2014-11-26
AU2007307057B2 (en) 2011-09-15
AU2007307057A1 (en) 2008-04-17
DK2084174T3 (en) 2013-11-04
PT2084174E (en) 2013-10-08
US20100056770A1 (en) 2010-03-04
CN101600725A (en) 2009-12-09
KR101057239B1 (en) 2011-08-16
IL198086A0 (en) 2009-12-24
IL198086A (en) 2012-03-29
HK1133889A1 (en) 2010-04-09
RU2421461C2 (en) 2011-06-20

Similar Documents

Publication Publication Date Title
EP2084174B1 (en) Preparation of nucleosides ribofuranosyl pyrimidines
Mansuri et al. Preparation of 1-(2, 3-dideoxy-. beta.-D-glycero-pent-2-enofuranosyl) thymine (d4T) and 2', 3'-dideoxyadenosine (ddA): general methods for the synthesis of 2', 3'-olefinic and 2', 3'-dideoxy nucleoside analogs active against HIV
JP2010505954A5 (en)
EP2855497B1 (en) Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds
WO1988007532A1 (en) 2&#39;,3&#39; dideoxyribofuranoxide derivatives
IL176075A (en) Process for producing fluorocytidine derivatives and some such compounds
JP5766703B2 (en) Synthesis of decitabine
EP0193903A2 (en) Production of cytosine nucleosides
CN1137892C (en) Preparation of N-9 substituted guanine compound
JP5550234B2 (en) Method for producing furanose derivatives
JP2009526782A (en) Method for producing gemcitabine and related intermediates
US6933382B2 (en) Process for the synthesis of 2-deoxy-D-glucose
WO2007070804A2 (en) Process for preparing gemcitabine and associated intermediates
US6897302B2 (en) Method for synthesizing β-L-5-fluoro-2′,3′-dideoxy-2′,3′-didehydrocytidine (β-L-FD4C)
Richardson et al. Synthesis and properties of psico-nucleosides
EP1960378A1 (en) A manufacturing process of 2&#39;,2&#39;-difluoronucleoside and intermediate
Maougal et al. Synthesis of conformationally constrained nucleoside analogues
TĂNASE et al. A NEW WAY TO NUCLEOSIDES WITH AN OXABICYCLO [3.3. 0] OCTANE SCAFFOLD FROM AN ADVANCED INTERMEDIATE IN THE SYNTHESIS OF THE PROSTAGLANDIN ANALOG, CLOPROSTENOL
WO2008026222A2 (en) Process and intermediates of 2,2&#39; difluoronucleosides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780037855.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839369

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007307057

Country of ref document: AU

Ref document number: 198086

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2666098

Country of ref document: CA

Ref document number: MX/A/2009/003795

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009532372

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 817/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020097008991

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007307057

Country of ref document: AU

Date of ref document: 20071005

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007839369

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009117396

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12444608

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0719174

Country of ref document: BR

Free format text: REGULARIZE O DOCUMENTO DE CESSAO DO DIREITO DE PRIORIDADE REFERENTE A PRIORIDADE "US 60/850,962" DE 10/10/2006, QUE FOI APRESENTADO NA PETICAO NO. 020090056698 DE 08/06/2009, APRESENTANDO A CESSAO DO DIREITO DE PRIORIDADE DOS INVENTORES/DEPOSITANTES DA PRIORIDADE "US 60/850,962" DE 10/10/2006 ("STEVEN D. AXT", "KESHAB SARMA", "JUSTIN VITALE", "JIANG ZHU" E "QINGWU JIN") PARA O DEPOSITANTE "PHARMASSET, INC." E DOS INVENTORES/DEPOSITANTES DA PRIORIDADE "US 60/850,962" DE 10/10/2006 ("BRUCE ROSS", 'SUGUNA RACHAKONDA" E "BYOUNG-KWON CHU") PARA O DEPOSITANTE "F. HOFFMANN-LA ROCHE AG".

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0719174

Country of ref document: BR

Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2257 DE 08/04/2014, PARA QUE POSSA SER ACEITO A COPIA DO DOCUMENTO DE PRIORIDADE DISPONIVEL NA FASE INTERNACIONAL COMO UM DOCUMENTO DE CESSAO DOS DIREITOS DA PRIORIDADE, APRESENTE DOCUMENTOS QUE COMPROVEM A ALTERACAO DE NOME DO DEPOSITANTE "ROCHE PALO ALTO LLC" PARA "F. HOFFMANN LA-ROCHE AG".

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: PI0719174

Country of ref document: BR

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: PI0719174

Country of ref document: BR

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0719174

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090409